Melanotan 1 (MT-1), also known as afamelanotide, is a synthetic analogue of alpha-melanocyte-stimulating hormone (α-MSH). It is a 13-amino acid peptide that binds melanocortin receptors with high affinity, making it a subject of research interest in pigmentation biology, photoprotection, and melanocortin system studies.
Melanocortin Receptor Biology
Five melanocortin receptor subtypes (MC1R through MC5R) have been identified, each with distinct tissue distribution and functional profile. MC1R, expressed primarily in melanocytes, mediates pigmentation responses. MC3R and MC4R are expressed in the central nervous system and have been studied in the context of energy homeostasis and feeding behavior. MC2R is the primary ACTH receptor in the adrenal cortex.
Alpha-MSH is the endogenous agonist at MC1R, MC3R, MC4R, and MC5R. Melanotan 1 is a linear analogue of α-MSH with enhanced receptor binding affinity and extended biological half-life compared to the endogenous peptide.
Pigmentation Research
The primary research application of MT-1 involves melanogenesis — the production of melanin in melanocytes. MC1R activation by α-MSH or its analogues initiates a signaling cascade through cAMP that upregulates microphthalmia-associated transcription factor (MITF), which in turn drives expression of melanogenic enzymes including tyrosinase.
Research in melanocyte cell cultures and rodent skin models has documented dose-dependent increases in melanin production following MT-1 administration, with the compound demonstrating greater potency than endogenous α-MSH due to its enhanced receptor binding characteristics.
Photoprotection Research
Beyond direct melanin induction, MT-1 has been examined for its potential to reduce UV-induced DNA damage in skin research models. Melanin functions as a UV chromophore, absorbing radiation before it reaches nuclear DNA. Research in murine models examined whether pharmacologically enhanced melanization reduces UV-induced pyrimidine dimer formation — a marker of UV-induced DNA damage.
Erythropoietic Protoporphyria Research
MT-1 has received the most clinical research attention in the context of erythropoietic protoporphyria (EPP), a rare metabolic disorder characterized by extreme photosensitivity. Afamelanotide (the clinical designation for MT-1) has been evaluated in multiple clinical trials, with published data demonstrating increased pain-free sun exposure time in EPP patients.
MC4R and Energy Homeostasis
While MT-1 is primarily studied for its MC1R-mediated effects, its activity at MC4R — expressed in hypothalamic circuits regulating food intake and energy expenditure — has generated parallel research interest in metabolic biology.
All research referenced in this post was conducted under controlled laboratory or clinical trial conditions and does not represent evidence of therapeutic efficacy for any indication outside the approved EPP indication for afamelanotide.